Boulder, Colorado - July 16, 2007 - Bolder BioTechnology, Inc. is pleased to announce that it has been granted patents 7,214,779 and 7,232,885 by the U.S. Patent and Trademark Office. Joe Cox, Company President commented "These patents broaden the scope of intellectual property protection for our long-acting, second generation granulocyte-macrophage colony-stimulating factor (GM-CSF) analog and granulocyte colony-stimulating factor (G-CSF) analog programs. G-CSF and GM-CSF are human proteins that cause bone marrow cells to divide and differentiate into mature white blood cells. Recombinant forms of these proteins are used in a variety of clinical settings characterized by low numbers of white blood cells, such as in cancer patients receiving chemotherapy. Preclinical studies indicate that our long-acting G-CSF and GM-CSF analogs can be administered less frequently, but with comparable or improved efficacy compared to first generation G-CSF and GM-CSF products, which must be administered daily. We believe our products have the potential to compete very favorably in the worldwide G-CSF/GM-CSF markets, which have combined annual sales of over $4 billion."
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. Research leading to the development of the Company's long acting GM-CSF and G-CSF analogs has been supported by Small Business Innovation Research (SBIR) grants awarded to Bolder BioTechnology by the National Cancer Institute of the National Institutes of Health. For additional information about Bolder BioTechnology, Inc., please visit our web site at www.bolderbio.com.
Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.
Contact information: Joe Cox, Ph.D., President (303) 420-4420 ext.202